Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0024-4.11%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.66M | -1.24M | -7.79M | -7.90M | -12.46M |
| Total Depreciation and Amortization | -- | -- | -- | -- | 0.00 |
| Total Amortization of Deferred Charges | 419.00K | 152.40K | 173.40K | 301.80K | 415.20K |
| Total Other Non-Cash Items | 3.36M | 56.60K | 6.45M | 6.37M | 10.18M |
| Change in Net Operating Assets | -130.10K | -84.60K | -135.00K | -86.30K | 833.70K |
| Cash from Operations | -1.01M | -1.11M | -1.30M | -1.32M | -1.03M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 915.00K | 1.12M | 1.46M | 1.41M | 593.20K |
| Total Debt Repaid | 0.00 | -35.00K | -35.00K | -35.00K | 525.00K |
| Issuance of Common Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.00K | -75.00K | -125.00K | -125.00K | -75.00K |
| Cash from Financing | 890.00K | 1.01M | 1.30M | 1.25M | 1.04M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -119.00K | -109.60K | -1.40K | -71.00K | 14.20K |